Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21855473 | 0.84 | — | — | |
| SCHEMBL29619215 | 0.75 | AHR (0.49) | CDK2CDK5CDK5R1 | |
| SCHEMBL20541825 | 0.75 | AHR (0.49) | CDK2CDK5CDK5R1 | |
| SCHEMBL21855481 | 0.75 | CDK2 (0.36) | CDK2CDK5CDK5R1 | |
| SCHEMBL21855483 | 0.74 | CDK2 (0.38) | CDK2CDK5CDK5R1 | |
| SCHEMBL23713346 | 0.73 | CDK2 (0.36) | CDK2CDK5CDK5R1 | |
| SCHEMBL23381599 | 0.72 | CDK2 (0.31) | CDK2CDK5CDK5R1 | |
| SCHEMBL15224428 | 0.70 | CDK2 (0.34) | CDK2CDK5CDK5R1 | |
| SCHEMBL15238119 | 0.69 | CDK2 (0.40) | CDK2CDK5CDK5R1 | |
| SCHEMBL29174908 | 0.68 | CDK2 (0.36) | CDK2CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144839-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| WO-2020081636-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-04-23 | — | — | WO | disclosed |
| WO-2020081636-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144839-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | CDK2 1444/4885CDK5 1931/4885CDK5R1 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.